Generic Medicine Info
Indications and Dosage
Adult: 1 mg daily. If necessary, after 1 mth, dose may be increased to 2 mg daily given in divided doses.
Should be taken on an empty stomach.
Special Precautions
Cerebrovascular disease, ischaemic heart disease, renal impairment, occlusive peripheral vascular disorders, history of depression. May impair ability to drive or operate machinery. Sudden withrawal may cause rebound hypertension, do not discontinue until several days after the withdrawal of β-blocker when used together.
Adverse Reactions
Drowsiness, dry mouth, dizziness, headache, constipation, depression, anxiety, fatigue, nausea, anorexia, parotid pain, sleep disturbances, vivid dreams, impotence and loss of libido, urinary retention or incontinence, slight orthostatic hypotension, fluid retention.
Drug Interactions
TCAs may antagonise the hypotensive effects of rilmenidine. Additive antihypertensive effects when used with antipsychotics and other antihypertensives. Increased sedation when used with alcohol or other CNS depressants.
Lab Interference
Transient abnormalities in liver function tests.
Description: Rilmenidine is a centrally-acting antihypertensive. It acts through stimulation of central imidazoline receptors and has α2-adrenoceptor agonist activity.
Absorption: Rapidly and extensively absorbed.
Distribution: Large distribution, with a Vd of 5.13 L/kg.
Metabolism: No hepatic first pass effect after oral admin.
Excretion: Elimination half-life: about 8 hr. Mainly via renal route as unchanged compound.
MIMS Class
Other Antihypertensives
Disclaimer: This information is independently developed by MIMS based on Rilmenidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in